Last reviewed · How we verify
NCT05347043: EvaCAD
The Montreal Cognitive Assessment.Test in Adults With Sickle Cell Disease
NA trial testing Montreal cognitive assessment in Sickle Cell Anemia in 65 participants. Completed in 14 October 2024.
11 April 2024
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 65 |
| Start date | 20 October 2022 |
| Primary completion | 11 April 2024 |
| Estimated completion | 14 October 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Montreal cognitive assessment
Conditions studied
- Sickle Cell Anemia — all drugs for Sickle Cell Anemia →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
18 and older, any sex, with Sickle Cell Anemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the performances of the Montreal Cognitive Assessment (MoCA) to screen for cognitive impairment in adults with sickle cell anemia. The results of the MoCA and its subscores will be compared to a standardized neuropsychological evaluation using validated tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05347043
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Montreal cognitive assessment
Trials testing the same drug.
- NCT06068296 — Short-term Memory Assessment in Patients With Poststroke Aphasia · NA · completed
Other recruiting trials for Sickle Cell Anemia
Currently open trials in the same condition.
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT07356050 — Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children Wit · recruiting
- NCT05675436 — Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease · active not recruiting
- NCT06529874 — Pressure Pain Tolerance in Relation to Balance and Strength in Children · NA · recruiting
- NCT07116772 — Serial Assessment of Fertility Experiences · recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05347043 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05347043.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing